BioSpace News Archive

Kintara Therapeutics, Inc announces today that its Chief Executive Officer, Robert E. Hoffman , will present a corporate overview at the Q4 Investor Summit Conference, which is being held virtually on November 16 – 17, 2021

ABVC BioPharma, Inc. today announced the receipt of $4,245,000 in additional gross proceeds from the exercise of Series A warrants issued in the company’s August 3, 2021, public offering of securities.

a $45 million Series B fundraise, announced in September 2021, and commercialization of its ActivInsights™ software suite, which is targeted for early 2022.

Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today reported financial results for the third quarter ended September 30, 2021.

Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Q4 Investor Summit Conference, which is being held virtually on November 16 – 17, 2021.

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that two abstracts relating to GMI-1359, the Company’s dual antagonist of CXCR4 and E-selectin, have been accepted for poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 11-14, 2021.

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present a company overview at the H.C. Wainwright 7th Annual Israel Virtual Conference.

NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced activities at the upcoming 2021 Radiology Society of North America (RSNA) Annual Meeting, being held virtually and on-site at McCormick Place in Chicago from Nov. 28 – Dec. 2.

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, reported topline results from the Company’s Phase 2 clinical trial of Brilacidin in hospitalized patients with moderate-to-severe COVID-19.

The AAO’s Laureate Award, the Academy’s single highest honor, is awarded to ophthalmologists who distinguish themselves and the profession by making exceptional scientific contributions toward preventing blindness and restoring sight worldwide.